Last reviewed · How we verify

POZEN — Portfolio Competitive Intelligence Brief

POZEN pipeline: 4 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 3 Phase 3 0 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
celebrex celebrex marketed 3-phosphoinositide-dependent protein kinase 1, Adenosine receptor A3, Cytochrome c oxidase subunit 2 Immunology
aspirin and [NSAID] aspirin and [NSAID] marketed NSAID combination Cyclooxygenase (COX-1 and COX-2) Pain management / Cardiovascular
Sumatriptan and Naproxen sodium Sumatriptan and Naproxen sodium marketed Triptan/NSAID combination 5-HT1B/1D receptors (sumatriptan); COX-1/COX-2 (naproxen sodium) Neurology
EC Aspirin 325 EC Aspirin 325 marketed Antiplatelet agent / NSAID Cyclooxygenase (COX-1, COX-2) Cardiovascular
PA32540 PA32540 phase 3 Fixed-dose combination analgesic (acetaminophen + NSAID) COX-1 and COX-2 (NSAID component); central pain pathways (acetaminophen component) Pain Management
Rescue Antacid Rescue Antacid phase 3 Antacid Gastroenterology
PN 400 (VIMOVO) PN 400 (VIMOVO) phase 3 NSAID-proton pump inhibitor combination Gastrointestinal

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amorphical Ltd. · 1 shared drug class
  2. Baim Institute for Clinical Research · 1 shared drug class
  3. Barcelona Institute for Global Health · 1 shared drug class
  4. Bosnalijek D.D · 1 shared drug class
  5. HALEON · 1 shared drug class
  6. Isfahan University of Medical Sciences · 1 shared drug class
  7. Merck Sharp & Dohme LLC · 1 shared drug class
  8. PLx Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for POZEN:

Cite this brief

Drug Landscape (2026). POZEN — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pozen. Accessed 2026-05-14.

Related